Drug intelligence / Profile preview

Cytolin

Development stage: Preclinical
Lead developer: CytoDyn
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Cytolin is an anti-HIV monoclonal antibody developed by CytoDyn Inc. It is designed as a therapy for immune deficiency viruses, specifically HIV/AIDS. The drug targets CCR5 receptors, which are co-receptors used by HIV to enter cells. CytoDyn Inc. has pursued regulatory advice and strategic planning for an Investigational New Drug (IND) application to facilitate human trials for Cytolin.

Brand names: Cytolin®

Targets

CCR5 (C-C chemokine receptor type 5)

Beyond the preview

Go deeper on Cytolin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytolin.

Explore the full profile